



SHAREABLE PDF

# Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers

Duncan Keeley<sup>1</sup>, Jane E. Scullion<sup>2</sup> and Omar S. Usmani<sup>3</sup>

**Affiliations:** <sup>1</sup>Thame, UK. <sup>2</sup>University Hospitals of Leicester NHS Trust, Leicester, UK. <sup>3</sup>National Heart and Lung Institute, Imperial College London, London, UK.

**Correspondence:** Omar Usmani, Imperial College London and Royal Brompton Hospital, National Heart and Lung Institute (NHLI), Airways Disease Section, Dovehouse Street, London SW3 6LY, UK. E-mail: o.usmani@imperial.ac.uk



@ERSpublications

**Uncritical implementation of policy risks deterioration in patient inhaler choice** <http://bit.ly/2RluJti>

**Cite this article as:** Keeley D, Scullion JE, Usmani OS. Minimising the environmental impact of inhaled therapies: problems with policy on low carbon inhalers. *Eur Respir J* 2020; 55: 2000048 [<https://doi.org/10.1183/13993003.00048-2020>].

This single-page version can be shared freely online.

As global citizens, we have a duty to reduce the serious threats posed to planetary well-being and population health by environmental degradation and climate change. These now unquestionable threats to our future are due to human population growth and the resource consumption patterns of the human race. In tandem, as healthcare professionals, we should seek the best possible outcomes of our treatment for our patients and we need to consider equity between different groups of patients. In the speciality of respiratory medicine, the current controversy over how to deal with the role in global warming of the propellants used in pressurised metered dose inhalers (pMDIs) is a very pressing example of how these sometimes conflicting imperatives confront us in our daily practice.